

**CURRICULUM VITAE**

Rev 02/2007

**NAME** James D. Ahlgren

**ADDRESS**

**OFFICE** Div. of Hematology and Oncology  
The George Washington University Medical Center  
2150 Pennsylvania Ave. NW #3-428  
Washington, DC 20037

(202) 741-2478  
(202) 741-2487 (fax)

**EDUCATION AND TRAINING**

1955 B.Sc. (Electrical Engineering)  
Massachusetts Institute of Technology  
Cambridge, MA

1977 M.D.  
Georgetown University School of Medicine  
Washington, DC

1977-1979 Intern, Resident in Medicine  
Georgetown University Hospital  
Washington, DC

1979-1981 Fellow, Medical Oncology  
Georgetown University Hospital  
Washington, DC

**EXPERIENCE**

1994-Pres Professor of Medicine and Pharmacology  
The George Washington Univ. School of Medicine,  
Washington, DC

1991-94 Associate Professor of Pharmacology  
The George Washington Univ. School of Medicine,  
Washington, DC

1991-Pres Associate Director  
The George Washington University Cancer Center,  
Washington, DC

1988-94 Associate Professor of Medicine  
The George Washington Univ. School of Medicine,  
Washington, DC

1988-Pres      Staff Physician  
The George Washington Univ. Hospital, Washington, DC

1988-90        Adjunct Associate Professor of Pharmacology  
Georgetown Univ. School of Medicine, Washington, DC

1988            Associate Professor of Medicine and Pharmacology  
Georgetown Univ. School of Medicine, Washington, DC

1987-1988     Assistant Professor of Pharmacology  
Georgetown Univ. School of Medicine, Washington, DC

1987-1988     Acting Chief, Division of Medical Oncology  
Georgetown University Hospital, Washington, DC

1986-1988     Director, Medical Oncology Clinical Services  
Lombardi Cancer Research Center, Washington, DC

1983-1995     Chairman  
Mid-Atlantic Oncology Program, Washington, DC

1983-1988     Assistant Professor of Medicine  
Georgetown Univ. School of Medicine, Washington, DC

1982-1983     Executive Director  
Mid-Atlantic Oncology Program, Potomac, MD

1981-1989     Staff Physician  
Hospice of Northern Virginia, Arlington, VA

1981-1988     Staff Physician  
Georgetown University Hospital, Washington, DC

1981-1982     Instructor, Medicine  
Georgetown Univ. School of Medicine, Washington, DC

1963-1973     Vice President, President, Director  
Telcom Inc., Vienna, VA

1958-1963     Research Engineer, Asst. Dir. Research & Development  
Page Communications Engineers, Washington, DC

1956-1958     Chief, Circuit Design Section  
Reed Research Inc., Washington, DC

1954-1956     Engineer, Chief Engineer  
McIntosh Electronics Inc., Binghamton, NY

**CERTIFICATION**

American Board of Internal Medicine  
American Board of Internal Medicine (Medical Oncology Subspecialty)

## **LICENSURE**

District of Columbia #12851  
Virginia #030393

## **RESEARCH INTERESTS**

Carcinoid and neuroendocrine tumors  
Role of epidermal growth factor in solid tumors  
Role of suppressor gene products in oncogenesis  
Molecular mechanisms of fluorinated pyrimidines  
Clinical trials in gastrointestinal oncology

## **TEACHING ACTIVITIES**

Organizer, Intl Conf on Gastrointestinal Oncology 1993-present  
Lecturer in Pharmacology (Cancer Chemotherapy) 1986-1990  
Course Director, Gastrointestinal Oncology 1990  
Lecturer in Medical Oncology 1988-present  
Teaching Attending Physician in Medicine 1981-present  
Instructor, Physical Diagnosis 1981-1985, 1997-1999  
Lecturer, GWU Medical Oncology Board Review Course 1987-present  
Lecturer, GWU Hematology Board Review Course 1988-1994

## **SERVICE AND COMMITTEES**

Cancer Center Steering Committee 1990-95  
Cancer Committee 1988-present  
Research Committee 1989-90  
Research Committee, Subcommittee on Scientific Merit 1986-1988  
Medical Intern Selection Committee 1983-1984  
Medical Records Committee 1983-1986  
Ethics Committee, Department of Medicine 1987-1988  
Ad Hoc Committee to Review Cancer Center Policies 1988  
Ad Hoc Committee on Handling of Cytotoxic Drugs (Chairman) 1988  
Board of Directors, Mid-Atlantic Oncology Program 1983-95

## **ORGANIZATIONS**

American Society of Clinical Oncology  
American College of Physicians  
Institute of Electrical and Electronic Engineers  
American Geophysical Union  
American Meteorological Society  
Philosophical Society of Washington

## **HONORS**

Alpha Omega Alpha (elected 1977)  
Department of Medicine Academic Award (Georgetown Univ, 1977)  
Edward B. Bunn Award (Georgetown University, 1977)  
Jonathan M. Wainwright Award (Scranton, PA, 1993)  
Elaine H. Snyder Cancer Research Award (George Washington Univ, 1994)

## **RESEARCH GRANTS AWARDED**

National Cancer Institute: Support for Mid-Atlantic Oncology Program.  
5-U10-CA33075 1984-1986 (PI).

National Cancer Institute: Support for Mid-Atlantic Oncology Program,  
a CCOP Research Base. CA37424 1983-1986 (PI).

Office of Naval Research: Prostate Cancer Vaccine Clinical Study.  
2000-2003. N00014-00-1-0787 (Co-I).

Immunex: Phase II trial of 17-1A monoclonal antibody + GM-CSF in 5FU-  
resistant colorectal cancer. 1995-2000 (PI).

Sandoz Pharmaceuticals: Phase III trial of infusional 5FU ± SMS 201-  
995 LAR in pancreatic cancer. 1996-97 (PI).

Henri Beaufour Institute USA Inc: Phase II trial of lanreotide in  
neuroendocrine tumors. 1994-1996.

Henri Beaufour Institute USA Inc: Action of AcSDKP as a chalone-like  
regulator of hematopoiesis. 1993-95 (PI).

Schering: Phase II trial of protracted infusional 5FU and alpha  
interferon in metastatic colorectal cancer. 1994-96 (PI).

U.S. Bioscience: Intracellular 5FU metabolite levels in patients  
resistant to 5FU-based chemotherapy. 1991-92 (PI).

Schering: Phase II trial of protracted infusional 5FU and alpha  
interferon in advanced carcinoid. 1990-93 (PI).

U.S. Bioscience: Phase III trial of protracted infusional 5FU ± PALA  
in advanced colorectal carcinoma. 1989-93 (PI).

Bristol Laboratories: Phase II trial of protracted infusional 5FU and  
cisplatin in colorectal carcinoma. 1986-1987 (PI).

SKF Labs: Unrestricted Research Grant. 1986-1987 (PI).

Bristol Laboratories: Phase III trial of protracted infusional 5FU ±  
cisplatin in colorectal carcinoma. 1986-1989 (co-PI).

Ciba-Geigy: Phase II trial of aminoglutethimide in advanced ovarian  
carcinoma. 1985-1986 (PI).

Mead-Johnson: Phase II trial of megestrol acetate in advanced ovarian  
carcinoma. 1984 (PI).

Schering: Phase II trial of high-dose alpha interferon in colon  
carcinoma. 1981-1983 (PI).

## **PUBLICATIONS**

1. Ahlgren JD, Manz HJ, Harvey JC. Myopathy of chronic organophosphate poisoning: a clinical entity? Southern Med J 1979; 72:555-9.
2. Ahlgren JD, Smith FP, Kerwin DM, Sikic BI, Weiner JH, Schein PS. Pulmonary disease as a complication of chlorozotocin chemotherapy. Cancer Treat Rep 1981; 65:223-9.
3. Ahlgren JD, Schein PS. Chemotherapy and immunotherapy of gastrointestinal cancer. Practical Gastroenterology 1981; 5:18-25.
4. Green D, Ahlgren JD, Schein PS. A molecular basis for differences in nitrosourea bone marrow toxicity. In: Serrou B, Schein P, Imbach JL, eds. Nitrosoureas in Cancer Treatment. Amsterdam: Elsevier, 1981.
5. Ahlgren JD. On the molecular basis of oncogenesis. J Theor Biol 1981; 91:215-23.
6. Ahlgren JD, Green DC, Tew KD, Schein PS. Repair of DNA alkylation induced in L1210 leukemia and murine bone marrow by three nitrosoureas. Cancer Res 1982; 42:2605-8.
7. Schein PS, Smith FP, Woolley PV, Ahlgren JD. Current management of advanced and locally unresectable gastric carcinoma. Cancer 1982; 50:2590-6.
8. Vu VT, Tew KD, Ahlgren JD, Byrne PJ, Wang AL, Green DC, Schein PS. Chloroethylnitrosourea interaction with chromatin is a potential mechanism for bone marrow-sparing effect of the glucose analogs. Cancer Treat Symp 1983; 1:37-43.
9. Ahlgren JD, Schein PS, eds. Emcyt (Estramustine Phosphate Sodium): Proceedings of a Symposium April 24, 1983. Semin Oncol 1983; 10 (suppl 3).
10. Ahlgren JD. Estramustine - current status, 1983. Semin Oncol 1983; 10 (suppl 3):46-7.
11. Silgals RM, Ahlgren JD, Neefe JR, Rothman J, Rudnick S, Galicky FP, Schein PS. A phase II trial of high dose intravenous interferon alpha-2 in advanced colorectal cancer. Cancer 1984; 54:2257-61.
12. Woolley PV, Ahlgren JD, Byrne PJ, Priego VM, Schein PS. A phase I trial of spirogermanium administered in a continuous infusion schedule. Invest New Drugs 1984; 2:305-9.

13. Woolley PV, Smith FP, Neefe JR, Ahlgren JD, Byrne PV, Schein PS. Clinical overview of treatment for gastrointestinal tumors. In: Kimura K, Fujii S, Ogawa M, Bodey GP, Alberto P, eds. Fluoropyrimidines in Cancer Therapy. Amsterdam: Excerpta Medica, 1984.
14. Ahlgren JD, Schein PS. Neoplasms of the hepatobiliary system. In: Calabresi P, Schein PS, Rosenberg S, eds. Medical Oncology. New York: MacMillan, 1985:851-74.
15. Goldberg RM, Ayoob M, Silgals R, Ahlgren JD, Neefe JR. A phase II trial of lymphoblastoid interferon in metastatic malignant melanoma, Cancer Treat Rep 1985; 69:813-6.
16. Treat JA, Ahlgren JD, Woolley PV. Cancer of the large bowel and hepatobiliary system. In: Pinedo HM, Chabner BA, eds. Cancer Chemotherapy. Amsterdam: Elsevier, 1985; 7:332-41.
17. Harvey JH, McFadden M, Andrews WG, Byrne PJ, Ahlgren JD, Woolley PV. A phase I study of echinomycin (quinomycin A), NSC-526417, administered on an intermittent bolus schedule. Cancer Treat Rep 1985; 69:1365-8.
18. Goldberg RM, Smith FP, Ueno W, Ahlgren JD, Schein PS. 5-Fluorouracil, Adriamycin and mitomycin-C (FAM) in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 1986; 4:395-9.
19. Ahlgren JD, Smith FP, Cazap E, Estevez RE, Woolley PV, Wilkosky T, Stein J, Schein PS. FAM (5-FU, doxorubicin, mitomycin-C) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan-American Health Organization. Cancer Treat Rep 1987; 71:419-20.
20. Treat J, Ahlgren JD, Woolley PV: Cancers of the large bowel and hepatobiliary system. In: Pinedo HM, Chabner BA, eds. Cancer Chemotherapy. Amsterdam: Elsevier, 1987:264-70.
21. Falchuk SC, Ahlgren JD, Holt RW. Acute thyroiditis as a complication of chemotherapy administration through a Hickman catheter. Cancer Treat Rep 1987; 71:788-90.
22. Lokich JJ, Ahlgren JD, Gullo J, Phillips JA, Fryer JG. A prospective randomized comparison of continuous infusion 5-fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7:425-32.
23. Treat J, Falchuk SC, Woolley PV, Ahlgren JD, Neefe JR, Smith FP, Macdonald JS, Schein PS. Therapy of advanced gastric carcinoma: the Georgetown-Lombardi Center experience. Am J Clin Oncol 1989; 12:162-8.

24. Zeman RK, Dritschilo A, Silverman PM, Clark LR, Garra BS, Thomas DS, Ahlgren JD, Smith FP, Korec SM, Nauta RJ et al. Dynamic CT vs 0.5 T MR imaging in the detection of surgically proven hepatic metastases. *J Comput Assist Tomogr* 1989; 13:637-44.
25. Golden L, Ahlgren JD, Kattah J, Smith JW, Sisk R, Deeb Z. Cochleovestibular toxicity related to dichloromethotrexate. *Cancer Invest* 1989; 7:345-8.
26. Holt RW, Petrelli ES, Evans SRT, Ahlgren JD. Intraperitoneal chemotherapy complicated by Tenckhoff catheter erosion into the colon. *Southern Med J* 1989; 82:914-6.
27. Ahlgren JD. Lung cancer. In: Lokich JJ, ed. *Cancer Chemotherapy by Infusion* (2nd ed). Chicago: Precept Press, 1990:400-20.
28. Lokich JJ, Ahlgren JD, Cantrell J, Heim W, Wampler GL, Gullo JJ, Fryer JG, Alt DE. A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. *Cancer* 1991; 67:14-9.
29. Ahlgren JD, Trocki O, Gullo JJ, Goldberg R, Muir WA, Schacter L. Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. *Cancer Invest* 1991; 9:27-33.
30. Ahlgren JD. Combination chemotherapy by infusion in solid tumors. In: Rotman M, Rosenthal CJ, eds. *Concomitant Continuous Infusion Chemotherapy and Radiation*. Berlin: Springer-Verlag, 1991:35-47.
31. Wampler GL, Heim WJ, Ellison NM, Ahlgren JD, Fryer JG. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: A Mid-Atlantic Oncology Program study. *J Clin Oncol* 1991; 9:1438-45.
32. Rothman H, Cantrell JE Jr, Lokich J, Difino S, Harvey J, Ahlgren J, Fryer J. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma: a Mid-Atlantic Oncology Program study. *Cancer* 1991; 68:264-8.
33. Heim W, Wampler GL, Lokich JJ, Brereton HD, Scialla SJ, LaLuna F, Ahlgren JD, Nevin J, Fryer JG, Alt D. A study of infusional cisplatin and infusional 5-fluorouracil for locally advanced or metastatic non-small cell lung cancer: a Mid-Atlantic Oncology Program study. *J Clin Oncol* 1991; 9:2162-6.
34. Perlin E, Ahlgren JD. Pigmentary effects from the protracted infusion of 5-fluorouracil. *Int J Derm* 1991; 30:43-4.

35. Wampler GL, Ahlgren JD, Lokich JJ, Gullo JJ, Phillips JA. Dichloromethotrexate, infusional cisplatin, and infusional 5-fluorouracil for locally advanced or metastatic non-small cell lung cancer. Am J Clin Oncol 1991; 14:442-5.
36. Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992.
37. Ahlgren JD. Principles of chemotherapy in gastrointestinal cancer. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:29-49.
38. Hill MC, Roberts IM, Ahlgren JD. Esophageal cancer: Detection and staging. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:81-7.
38. Ahlgren JD. Esophageal cancer: Chemotherapy and combined modalities. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:135-47.
40. Ahlgren JD, Hill MC, Roberts IM. Pancreatic cancer: Patterns, diagnosis and approaches to treatment. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:197-207.
41. Ahlgren JD. Pancreatic cancer: Chemotherapy of advanced disease. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:227-35.
42. Ahlgren JD. Pancreatic cancer: Combined modality approaches. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:237-40.
43. Ahlgren JD. Colorectal cancer: Chemotherapy. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:339-57.
44. Wanebo HJ, Ahlgren JD, Hill MC. Cancer of the biliary tract. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:399-416.
45. Ahlgren JD, Wanebo HJ, Hill MC. Hepatocellular carcinoma. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:417-36.
46. Harter KW, Ahlgren JD. Carcinoma of the anal canal and anal margin. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:437-47.

47. Fer MF, Abrams PG, Ahlgren JD, Weiden PL. Monoclonal antibodies in the imaging and treatment of gastrointestinal malignant disease. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:579-91.
48. Ahlgren JD, Schwab F. Regional therapy for gastrointestinal malignancies. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:615-26.
49. Wampler GL, Ahlgren JD, Schulof RS. A pilot study of intensive weekly chemotherapy for extensive disease small cell lung carcinoma. Cancer Invest 1992; 10:97-102.
50. Rosenthal CJ, Wampler GL, Brereton HD, Ahlgren JD, Lokich JJ, Fryer JG, Alt D. A study of oral etoposide, infusional cisplatin, and infusional 5-fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study. Am J Clin Oncol 1992; 15:12-17.
51. Goldberg SL, Ahlgren JD. Recent clinical experience with infusional etoposide. J Infusional Chemother 1991; 1:37-43.
52. Anderson LW, Parker RJ, Collins JM, Ahlgren JD, Wilkinson D, Strong JM. GC-MS method for routine monitoring of 5-fluorouracil in plasma of patients receiving low level protracted infusions. J Chromatography 1992; 581:195-201.
53. Ahlgren JD. Protracted infusional schedules of fluorouracil in colorectal cancer versus fluorouracil with modulators: differences and similarities. J Infusional Chemother 1992; 2:128-37.
54. Kemeny N, Lokich JJ, Anderson NR, Ahlgren JD. Recent advances in the treatment of advanced colorectal cancer. Cancer 1993; 71:9-18.
55. Ahlgren JD. Neoplasms of the hepatobiliary system. In: Calabresi P, Schein PS, eds. Medical Oncology (2nd ed). New York: McGraw-Hill, 1993:713-39.
56. Ahlgren JD. Chemotherapy. In: Wanebo HJ, ed. Colorectal Cancer. Chicago: Mosby-Year Book, 1993:523-39.
57. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler G, Yeung K-Y, Alt D, Fryer JG. Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11:1957-68.
58. Ahlgren JD. Why infusional chemotherapy in lung cancer? J Infusional Chemother 1994; 4:149-50.

59. Ahlgren JD. Chemotherapy for pancreatic cancer. *Cancer* 1996; 78:654-63.
60. Ahlgren JD. Etiology and risk factors in pancreatic cancer. *Semin Oncol* 1996; 23:241-50.
61. Ahlgren JD. Chemotherapy for advanced upper gastrointestinal malignancy (esophagus, stomach, pancreas). In: Wanebo HJ, ed. *Surgery for Gastrointestinal Cancer: A Multidisciplinary Approach*. Philadelphia: JB Lippincott, 1996:467-80.
62. Auerbach M, Wampler GL, Lokich JJ, Fryer D, Fryer JG, Ahlgren JD. Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: A Mid-Atlantic Oncology Program study. *Ann Oncol* 1997; 8:439-44.
63. Ahlgren JD. Gastrointestinal cancer in the elderly. *Clin Geriatr Med* 1999; 15:627-40.
64. Ahlgren JD. Genetics of pancreatic cancer: clues to pancreatic carcinogenesis. [Editorial] *Cancer Invest* 2001; 19:98-9.
65. Ahlgren JD. Gastrointestinal malignancies. *Prim Care* 2001; 3:647-60.
66. Ahlgren JD. The Berlin/Rothenberg article reviewed. [Editorial] *Oncology* 2001 15:1254-6.
67. Ahlgren JD. Thymidylate synthase in nodal metastases: prognostic for chemosensitivity but not for adjuvant therapy? [Editorial] *J Clin Oncol* 2005: 23:5452-4.

## **ABSTRACTS**

- A1. Ahlgren JD, Green DC, Tew KD, Saslaw LD, Schein PS. Repair of chloroethylnitrosourea-induced DNA lesions in murine bone marrow and L1210 cells. Proc Am Assoc Cancer Res 1981; 22:269.
- A2. Green DC, Ahlgren JD, Brereton HD, Schein PS. Alkylation of template-active chromatin in murine bone marrow (MBM) and P388 leukemia cells by chlorozotocin (CLZ) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU). Proc Am Assoc Cancer Res 1982; 23:165.
- A3. Ahlgren JD, Green DC, Tew KD, Schein, PS. Chloroethylnitrosourea binding to template active chromatin in murine bone marrow and two murine leukemias. Proc Intl Cancer Congr 1982; 13:384.
- A4. Silgals RM, Ahlgren J, Neefe J, Rothman J, Rudnick S, Galicky FP, Schein PS. Treatment of metastatic adenocarcinoma of the colon with recombinant interferon alpha-2. Proc Am Assoc Cancer Res 1983; 24:150.
- A5. Schein PS, Smith FP, Dritschilo A, Stablein DM, Ahlgren JD. Phase I-II trial of combined modality FAM (5-Fluorouracil, Adriamycin and mitomycin-C) plus split course radiation (FAM-RT-FAM) for locally advanced gastric (LAG) and pancreatic (LAP) cancer: a Mid-Atlantic Oncology Program study. Proc Am Soc Clin Oncol 1983; 2:126.
- A6. Ahlgren JD, Smith FP, Harvey J, Kales AN, Woolley PV, Schein PS. A Phase II Study of FAM (5-FU, Adriamycin and mitomycin-C) plus triazinate (T) for advanced measurable gastric carcinoma. Proc Am Soc Clin Oncol 1984; 3:145.
- A7. Bonnem EM, Brereton HB, Gullo JJ, Noble SK, Phalon AL, Novak JW, Ahlgren JD, Schein PS. Vindesine (V), Adriamycin (A), mitomycin-C (M) in the treatment of advanced adenocarcinoma of the lung. Proc Am Soc Clin Oncol 1984; 3:227.
- A8. Bonnem EM, Brereton HB, Noble SK, Ahlgren JD, Phalon AL, Novak JW, Schein PS. Vindesine (V) Adriamycin (A), platinum (P) in the treatment of advanced squamous cell carcinoma of the lung. A Mid-Atlantic Oncology Program study. Proc Am Soc Clin Oncol 1984; 3:227.
- A9. Smith LF, Ahlgren J, Ferraresi R, Spiegel RJ. Treatment of multiple solitary plasmacytomas with alpha-2-IFN recombinant DNA (Intron). Proc Am Soc Clin Oncol 1984; 3:270.
- A10. Ahlgren JD, Thomas D, Ellison N, Huberman M, Harvey J, Freeman A, Wilcosky T, Gillings D, Zaloudek C, Browder H, Noble S. Phase II evaluation of high dose megestrol acetate in advanced refractory ovarian cancer. Proc Am Soc Clin Oncol 1985; 4:124.

- A11. Citron M, Brereton H, Huberman M, Ahlgren J, Bernath A, Noble S, Freeman A, Phillips J. Randomized Phase II study of dichloromethotrexate (DCM) alone, DCM + low-dose cisplatin (CP) and DCM plus high-dose CP in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1985; 4:193.
- A12. Andrews WG, Harvey JH, McFadden M, Byrne PJ, Ahlgren JD, Woolley PV. A Phase I Study of Echinomycin (Quinomycin A), NSC 526417, administered on an intermittent bolus schedule. Proc Am Soc Clin Oncol 1985; 4:42.
- A13. Balseiro J, Harbert JC, Ahlgren JD. Strontium-89 therapy for bone pain secondary to metastatic prostate and breast cancer. Proc Soc Nuclear Med, 1985.
- A14. Lokich J, Gillings D, Gullo J, Kirshner J, Ahlgren J. Bolus versus infusional 5-fluorouracil (5-FU): a randomized clinical trial in advanced measurable colorectal cancer. Proc Am Soc Clin Oncol 1986; 5:83.
- A15. Bernard S, Noble S, Wilcosky T, Ahlgren J, Smith FP. A Phase II Study of ifosfamide (IFOS) plus N-acetyl cysteine (NAC) in metastatic measurable pancreatic adenocarcinoma (PC). Proc Am Soc Clin Oncol 1986; 5:84.
- A16. Citron M, Brereton H, Huberman M, Bernath A, Gullo J, Ahlgren J, Noble S, Askin F. Randomized Phase II study of dichloromethotrexate (DCM) alone, DCM + low-dose cisplatin (CP), and DCM + high-dose CP in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1986; 5:185.
- A17. Smith F, Noble S, White L, Woolley P, Ahlgren J. A pilot study of streptozotocin, mitomycin-C, 5-fluorouracil (SMF) plus radiation: SMF-RT-SMF for locally advanced pancreatic cancer (LAP). Proc Am Soc Clin Oncol 1986; 5:92.
- A18. Goldberg R, Smith F, Ueno W, Ahlgren J, Schein P. Treatment of adenocarcinoma of unknown primary with fluorouracil, adriamycin and mitomycin-C (FAM). Proc Am Soc Clin Oncol 1986; 5:129.
- A19. Lokich J, Ahlgren J, Gullo J, Phillips J, Fryer J. A randomized trial of standard bolus 5-FU vs protracted infusional 5-FU in advanced colon cancer. Proc Am Soc Clin Oncol 1987; 6:81.
- A20. Ahlgren J, Gray R, Rothschild N, Richardson C. Phase II study of continuous infusion 5-fluorouracil (CI 5-FU) plus weekly cisplatin (DDP) as second line therapy for advanced measurable colorectal adenocarcinoma. Proc Am Soc Clin Oncol 1987; 6:83.
- A21. Rothschild N, Gray R, Smith L, Matelski H, Ahlgren J. Phase II study of aminoglutethimide in advanced ovarian cancer. Proc Am Soc Clin Oncol 1987; 6:115.

- A22. LeChevalier T, Tremblay C, Ronesse J, Spielmann M, Rothschild N, Gray R, Ahlgren J, Byrne P, Woolley P. Phase II trial of methotrexate-FAM in adenocarcinoma of unknown primary. Proc Am Soc Clin Oncol 1987; 6:130.
- A23. Gray R, Rothschild N, Ahlgren J, Ellison N, Lokich J, Heim W. Phase II study of menogaril in non-small cell lung cancer. Proc Am Soc Clin Oncol 1987; 6:174.
- A24. Goldberg R, Ahlgren J. Treatment of metastatic malignant melanoma (MMM) with tiazofurin: a phase II study. Proc Am Soc Clin Oncol, 1988; 7:253.
- A25. Ahlgren JD, Phillips J, Fryer J, Carter WH, Ellison N, Gullo JJ, Lokich J, Smith LF, Wampler GL. Clinical significance of methotrexate (mtx) dose and mtx-5FU interval in CMF chemotherapy of metastatic breast cancer. A clinical trial using response surface methodology (RSM). Proc Am Soc Clin Oncol 1989; 8:38.
- A26. Cantrell J, Lokich J, Smith F, Ahlgren J. A phase II study of continuous infusion 5-fluorouracil (5-FU) and weekly (wkly) low-dose cisplatin (DDP) for advanced pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1989; 8:107.
- A27. Lokich J, Cantrell J, Ahlgren J, Phillips J. A phase III trial of protracted infusional 5-FU (PIF) versus PIF plus weekly bolus cisplatin (CDDP) in advanced measurable colorectal cancer (MAOP protocol 5286). Proc Am Soc Clin Oncol 1989; 8:104.
- A28. Ahlgren JD, Lokich JJ, Gullo JJ, Cantrell JE, Phillips JA, Fryer JG. Clinical trials of the Mid-Atlantic Oncology Program in the treatment of metastatic colorectal cancer with protracted infusional 5-fluorouracil (5-FU). Intl Congr Infusional Chemother, Bordeaux, 1989.
- A29. Goldberg RM, Ahlgren JD. Continuous infusion 5-FU with weekly low-dose cisplatin as second line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. Proc 2nd Intl Conf Gastrointest Cancer, Jerusalem, 1989.
- A30. Ahlgren JD, Lokich J, Schulz J, McCulloch W, Lynn J, Schein PS. Protracted infusion of 5-fluorouracil (5-FU) with weekly PALA: pilot study in metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 1990; 9:119.
- A31. Wampler GL, Heim WJ, Ellison NM, Ahlgren JD, Fryer JG. Subset analysis of extensive small cell lung cancer patients treated with a standard vs. an alternating regimen. Intl Conf Small Cell Lung Cancer, Ravenna, 1990.

- A32. Ahlgren JD, Fryer J, Carter WH, Wampler GL. Optimization of a 3-drug chemotherapy regimen by response surface methodology (RSM): a clinical trial of the Mid-Atlantic Oncology Program. DIA Conference on Optimization Methods in Drug Research and Development, Bethesda MD, 1990.
- A33. Schulof R, Lokich J, Wampler G, Schulz J, Ahlgren J. Phase II trial of protracted infusional 5-FU (PIF) for metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 1991; 10:170.
- A34. Heim W, Ahlgren J, Lokich J, Rosenthal CJ. Long term continuous infusion (CI) 5-fluorouracil (5-FU) in the treatment of metastatic prostate cancer: a phase II Mid-Atlantic Oncology Group (MAOP) study. Proc Am Soc Clin Oncol 1991; 10:179.
- A35. Manyak MJ, Ahlgren JD, McNellis RJ, Lynne J, Yu GW, Myers CE. Treatment of hormone resistant prostatic carcinoma with continuous infusion of suramin. J Urol, May 1992.
- A36. Ahlgren JD, Ellison N, Lokich J, Ueno W, Gottlieb R, Laluna F, Wampler G, Fryer J, Fryer D. High-dose tamoxifen (TAM): extended palliation in patients with chemoresistant epithelial ovarian cancer (EOC). A Mid-Atlantic Oncology Program (MAOP) study. Proc Am Soc Clin Oncol 1993; 12:258.
- A37. Ahlgren JD, Lokich J, Auerbach M, Wampler G, Schulz J, Fryer J, Fryer D. Protracted infusional 5FU (PIF): a well-tolerated regimen in metastatic renal carcinoma (MRC). A Mid-Atlantic Oncology Program (MAOP) study. Proc Am Soc Clin Oncol 1993; 12:244.
- A38. Ahlgren JD, Leming PD, Fryer D. Protracted infusional 5-FU (PIF) +  $\alpha$ 2b-interferon ( $\alpha$ -IFN): a well-tolerated regimen for palliation of advanced carcinoid. A Mid-Atlantic Oncology Program (MAOP) study. Proc Am Soc Clin Oncol 1993, 12:218.
- A39. Ahlgren JD, Bern M, Booth B, Fryer D. Protracted infusional 5FU (PIF): an active, well-tolerated regimen in metastatic adenocarcinoma of undetermined primary (AUP). A Mid-Atlantic Oncology Program (MAOP) study. Proc Am Soc Clin Oncol 1993; 12:401.
- A40. Nasim S, Ahlgren J, Radel M, Silverberg SG, Schwartz A, Wampler G, Garrett CT. Prognostic significance of p53 and K-ras mutations in lymph node negative colon carcinomas. Proc Am Assoc Cancer Res, 1993.
- A41. Fox KR, Glick JH, Macdonald JS, Vogel CL, Cartwright T, Auerbach M, Schulz JJ, Ahlgren JD, Heim WJ, Demers L, Reynolds RD, Mitchell EP, Capizzi RL, Schein P. Randomized phase II trial of rogletimide in advanced breast cancer. A preliminary report. 16th San Antonio Breast Cancer Symp, 1993.

- A42. Schulz J, Wampler G, Ahlgren J, Lokich J, Fryer D. A phase II trial of weekly intensive polychemotherapy in extensive small cell lung cancer: a study of the Mid-Atlantic Oncology Program (MAOP). Proc Am Soc Clin Oncol 1994; 13:340.
- A43. Ahlgren JD. Chemotherapy for advanced pancreatic cancer: no breakthrough in sight. Beaugard International Cancer Conference, Newport RI, 1994.
- A44. Ahlgren JD, Lokich JJ, Fryer JG, Fryer D, Conlan JC. A phase III trial of protracted 5FU (PIF) with or without weekly low-dose N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. Proc First International Conference on Gastrointestinal Oncology, Bordeaux, 1994.
- A45. Ahlgren JD, Nasim S, Wampler GL, Fryer D, Garrett CT. Correlation of mitotic activity with specific p53 mutations in Dukes' B colorectal cancer. Proc First International Conference on Gastrointestinal Oncology, Bordeaux, 1994.
- A46. Strong JM, Ahlgren JD, Anderson LW, Parker RJ, Wilkinson D. Plasma levels of 5-fluorouracil (5FU) during protracted intravenous infusion: instrumentation, variability, and relation to toxicity. Proc First Intl Conf Gastrointestinal Oncol, Bordeaux, 1994.
- A47. Ahlgren JD, Leming PD, Gullo JJ, Heim WJ, Lokich JJ, Fryer D. Protracted infusional 5-FU (PIF) +  $\alpha$ 2b-interferon ( $\alpha$ -IFN) in metastatic carcinoid: Updated experience with Mid-Atlantic Oncology Program (MAOP) study 5190. Proc Am Soc Clin Oncol 1995; 14:219.
- A48. Ahlgren JD, Cody RL, Roberts JD, Cohen G, Fryer D. Protracted infusional 5-FU (PIF) +  $\alpha$ 2b-interferon ( $\alpha$ IFN) in metastatic renal carcinoma. A Mid-Atlantic Oncology Program (MAOP) study. Proc Am Soc Clin Oncol 1995; 14:252.
- A49. Ahlgren JD. Chemotherapy regimens for gastric cancer based upon protracted infusional 5FU (PIF). Proc Second Intl Conf Gastrointestinal Oncol, Washington, 1995.
- A50. Ahlgren JD, Schulz JJ, Lokich JJ, Fryer JG, Fryer D, Conlan JC, Capizzi RL, Schein PS. Phase III trial of protracted infusional 5FU (PIF) with or without weekly low-dose N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program (MAOP) study. Proc Am Soc Clin Oncol 1996; 15:204.

- A51. Ahlgren JD, Wampler GL, Schulz JJ, Essig LJ, Heim WJ, Fryer D, Conlan J, Schein PS. Protracted infusional 5FU (PIF) with weekly PALA: An active, well-tolerated regimen for metastatic gastric cancer: A Mid-Atlantic Oncology Program (MAOP) study. Proc Am Soc Clin Oncol 1996; 15:204.
- A52. Lokich J, Auerbach M, Ahlgren J, Schulz J, Fryer J for the Mid-Atlantic Oncology Program (MAOP). Randomized trial of infusional (PIF) vs bolus 5-fluorouracil (BF) plus oral levamisole (L) in Dukes C colon cancer: comparison toxicity profile in initial entries. Proc Am Soc Clin Oncol 1996; 15:227.
- A53. Ahlgren JD, Auerbach M, Wampler JL, Lokich JJ, Fryer JG, Fryer D. Phase II trial of protracted infusional 5FU (PIF) plus weekly carboplatin in metastatic pancreatic carcinoma (MPC): A Mid-Atlantic Oncology Program (MAOP) study. Proc Third Intl Conf Gastrointestinal Oncol, Bordeaux, 1996.
- A54. Ahlgren JD. Combined modality treatment for pancreatic cancer. Proc 20th Intl Chemother Conf, Sydney, 1997.
- A55. Ahlgren JD. Protracted infusional 5FU: A schedule to maximize therapeutic ratio and synergy with radiation. Proc Fourth Intl Conf Gastrointestinal Oncol, Washington, 1997.
- A56. Ahlgren JD, Zimmerman K, Small CD, Tabbara IA. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1999; 18:24a [Abstract 88].
- A57. Ahlgren JD. What can we learn from the differing toxicities of the oral 5FU prodrugs? Proc 7th Intl Conf Gastrointestinal Oncol, Bordeaux, 2000.
- A58. Ahlgren JD, Siegel RS, Bishop C, Simmens S. Mitomycin-C (MMC), doxorubicin (DOX), and cisplatin (CDDP) plus protracted infusional 5-fluorouracil (PIF) (C-MAF) or capecitabine (XEL) (C-MAX): active in gastric cancer. Proc Am Soc Clin Oncol 2002 21:121b [Abstract 2296].
- A59. Siegel RS, Wilson WR, Ahlgren JD, Dmytrijuk A, Nguyen H, Bielasowicz S, Brunson J, Bank WO. A comprehensive regimen consisting of intra-arterial (IA) chemotherapy, intravenous (IV) chemotherapy and concurrent chemo-radiation therapy is effective in treating newly diagnosed patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2002; 21:187b [Abstract 2566].
- A60. Ahlgren JD, Siegel RS, Bishop C, Simmens S. Mitomycin-C, doxorubicin, and cisplatin plus protracted infusional 5-fluorouracil (C-MAF) or capecitabine (C-MAX): active chemotherapy in gastric carcinoma. Proc 9th Intl Conf Gastrointestinal Oncol, Arcachon, 2002.

- A61. Nahleh Z, Abdalla I, Kinsella V, Sharma K, Nguyen H, Siegel R, Ahlgren J. Outcome of 48 patients with advanced non small cell lung cancer (NSCLC) receiving gefinitib monotherapy after failing prior chemotherapy or as initial therapy. Proc Am Soc Clin Oncol 2003; 22:705 [Abstract 2837].
- A62. Ahlgren JD. Role of EGF in pancreatic cancer and a trial of second-line therapy with the EGFR-blocker gefitinib (ZD1839, Iressa). Proc 10th Intl Conf Gastrointest Oncol, Williamsburg, 2003.
- A63. Ahlgren JD. Current chemotherapy for metastatic colon cancer. 6th World Congress of the International Hepato-Pancreato-Biliary Association, Washington, 2004.
- A64. Ahlgren JD. Recent results with oral 5FU prodrugs in colorectal cancer. Proc 11th Intl Conf Gastrointestinal Oncol, Arcachon, 2004.